May. 15 at 10:18 PM
DexCom shares jumped around 7% during midday trading to
$61.99 after a wave of major corporate catalysts, led by activist investor Elliott Management, which built a significant stake in the continuous glucose monitoring (CGM) company and reached a cooperation agreement with its board.
Under the deal, Elliott will help appoint two new independent directors, signaling deeper governance involvement. The announcement coincided with DexCom’s 2026 Investor Day in Mesa, Arizona, where the company unveiled a new
$1 billion share buyback program replacing a prior authorization with
$250 million remaining.
Investor optimism was reinforced by management’s long-term strategy, which targets sustained double-digit growth as DexCom transitions from a diabetes-focused device maker into a broader biosensing leader. The company also outlined 2030 financial goals, including non-GAAP gross margins of 67–69%, operating margins of 29–30%, and adjusted EBITDA margins of 36–37%.
$DXCM